Breathe BioMedical has expanded its multi-center clinical study on breast cancer detection to Canada, partnering with the Vitalité Health Network [1, 2].
The expansion represents a shift toward non-invasive screening methods that could identify malignancies earlier than traditional diagnostic tools. If successful, this technology could reduce the reliance on more invasive procedures during the initial stages of cancer screening.
The study is based in Moncton, New Brunswick, where the Vitalité Health Network serves as the first Canadian site for the research [1, 2]. The project focuses on the development of a breath-analysis platform designed to detect the presence of breast cancer in women [1, 2].
Researchers are investigating how volatile organic compounds in a patient's breath can serve as biomarkers for the disease. This approach aims to provide a rapid, non-invasive alternative to current screening protocols, potentially increasing the frequency of testing due to the ease of the process [1, 2].
Breathe BioMedical is leading the multi-center effort to validate the accuracy and reliability of the platform across different populations [1, 2]. By integrating the Moncton site, the study gains access to a new demographic of participants, which is critical for the clinical validation of the diagnostic technology [1, 2].
The collaboration between the private biomedical firm and the Canadian health network is intended to accelerate the path toward regulatory approval and widespread clinical adoption [1, 2].
“A non-invasive breath-analysis platform that could detect breast cancer earlier than current methods.”
The integration of breath-analysis technology into clinical trials marks a move toward 'liquid biopsy' and volatile compound screening. By reducing the physical and psychological barriers associated with traditional breast cancer screenings, such technology could increase screening adherence and improve survival rates through earlier detection.
